DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Pivot X, Romieu G, Debled M. et al.
PHARE randomized trial final results comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer.
San Antonio Breast Cancer Symposium; 2018 Abstr. GS2-07
Access:
We do not assume any responsibility for the contents of the web pages of other providers.